Apogee Therapeutics, Inc. (APGE)
Automate Your Wheel Strategy on APGE
With Tiblio's Option Bot, you can configure your own wheel strategy including APGE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol APGE
- Rev/Share 0.0
- Book/Share 11.5707
- PB 3.6177
- Debt/Equity 0.0175
- CurrentRatio 15.8231
- ROIC -0.3527
- MktCap 2492095542.0
- FreeCF/Share -3.3187
- PFCF -12.9035
- PE -16.2347
- Debt/Assets 0.0165
- DivYield 0
- ROE -0.1874
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | APGE | Citigroup | -- | Buy | -- | $95 | March 13, 2025 |
News
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 132.7% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling
Read More
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%
Read More
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's is How to Trade
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Apogee Therapeutics Inc. (APGE) points to a 134% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO and BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will present at the Bank of America Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. / 4:40 p.m. E.T.
Read More
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report interim results from the Phase 1 APG990 healthy volunteer trial on Monday, March 3, 2025. Following the announcement, the Company will host a conference call and webcast at 8:30am ET to discuss the results and plans for …
Read More
About Apogee Therapeutics, Inc. (APGE)
- IPO Date 2023-07-14
- Website https://www.apogeetherapeutics.com
- Industry Biotechnology
- CEO Dr. Michael Thomas Henderson M.D.
- Employees 196